- $2.58bn
- $2.63bn
- $9.68m
Precigen, Inc. reports results for the quarter ended June 30 - Earnings Summary
Precigen posts quarterly profit as PAPZIMEOS sales surge
Precigen Inc expected to post a loss of 1 cent a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Advanced Energy, Bel Fuse, Cerebras
U.S. STOCKS ON THE MOVE-Klarna, Biogen, Legence
U.S. STOCKS ON THE MOVE-Cisco, Nvidia, Starbucks
Precigen surges after Q1 revenue beat, narrower loss
Precigen Q1 revenue beats estimates on PAPZIMEOS launch
Biopharmaceutical company Precigen Q3 net loss widens
U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, Vertiv
U.S. STOCKS ON THE MOVE-Broadcom, JPMorgan, Enpro
U.S. STOCKS ON THE MOVE-Bloom Energy, Argan, Endra Life Sciences
Precigen rises on long-term data of rare respiratory disease therapy
Brief: Precigen Reports Durable Responses With Papzimeos in Recurrent Respiratory Papillomatosis
U.S. STOCKS ON THE MOVE-Xcel Energy, Opendoor Technologies, Advance Auto Parts
U.S. STOCKS ON THE MOVE-Target, Precigen, Natgas companies
Precigen rises after US FDA approves drug for rare respiratory disease
U.S. STOCKS ON THE MOVE-Precigen, Twilio, Hims & Hers
Precigen rises after US FDA approves immunotherapy for rare respiratory disease